Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ACRS
ACLARIS THERAPEUTICS, INC.
NASDAQ
$6.01
▼ DOWN 2.44% (-0.15)

KEY STATISTICS

Market Cap$839.38 M
52w High$6.60
52w Low$1.74
Dividend Yield—
Frequency—
P/E-10.36
Volume1.22M
Shares Out.139.66M

COMPANY

LEADERSHIP

Neal S. Walker
CHIEF EXECUTIVE
Neal S. Walker

COMPENSATION 2026

Salary$615,000
Stock Awards$828,426
Incentive Plan Pay$350,550
All Other Comp.$0
Total$3,375,591

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 6, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
71

PRICE TARGET

Target High$12.00
Target Low$10.00
Target Median$10.50
Target Consensus$10.75

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$1.26M
NOV
5
THU

PRICE

$6.01 ▼ DOWN 2.44% (−$0.15)
$6.00$6.08$6.159:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM6.01

About Aclaris Therapeutics, Inc.

https://www.aclaristx.com ↗

Aclaris Therapeutics is a clinical-stage biopharma developing novel immuno-inflammatory therapies, including drugs for rheumatoid arthritis, psoriasis, hidradenitis, atopic dermatitis, autoimmune diseases, and cancer.

INDUSTRY

Biotechnology

A PRODUCT ACLARIS THERAPEUTICS, INC. IS KNOWN FOR

Bosakitug
Bosakitug

Bosakitug is an investigational monoclonal antibody targeting TSLP, developed by Aclaris Therapeutics, currently in Phase II for atopic dermatitis, aiming to treat immuno-inflammatory diseases.

COMPETITORS

COMPETITOR
AMGN COMPARE
AZN COMPARE
INCY COMPARE
REGN COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License and Service$2.81M $795K ▼$1.46M ▲$1.27M ▼
Contract research$485K $500K ▲$537K ▲$356K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
92
LISTED HERE
13
RANKED BY POSITION SIZE
VTS.AX
0.00% · 4.2M
IWM
0.02% · 3.1M
XS5G.L
0.06% · 946.4K
XPH
0.97% · 923.4K
FESM
0.07% · 802.5K
SBIO
0.43% · 172.8K
PRFZ
0.03% · 140.6K
DFAS
0.00% · 95.3K
RSSL
0.02% · 56.2K
GSSC
0.03% · 47.9K
PILL
0.65% · 26.0K
BIB
0.03% · 5.0K
RESM
0.03% · 329

INSTITUTIONAL OWNERSHIP

SHARES OWNED
63.05%
HOLDERS
204
TOP 12 OF 204 · RANKED BY POSITION SIZE
Bml Capital Management, LLC
14.3M sh · $27.07M
Ra Capital Management, L.P.
12.7M sh · $67.3M
Blackrock, Inc.
10.0M sh · $53.1M
Deep Track Capital, LP
9.3M sh · $49.44M
Vivo Capital, LLC
8.9M sh · $16.89M
Vanguard Group Inc
6.5M sh · $12.38M
Adage Capital Partners Gp, L.L.C.
5.3M sh · $10.03M
Frazier Life Sciences Management, L.P.
4.9M sh · $26.06M
Rock Springs Capital Management LP
4.6M sh · $8.76M
Morgan Stanley
4.1M sh · $7.75M
Decheng Capital LLC
4.0M sh · $21.38M
Balyasny Asset Management L.P.
3.4M sh · $12.6M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Kolbeck Roland Wilhelm
Sale · 12.4K shares
2026-08-01
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Kolbeck Roland Wilhelm
Sale · 36.4K shares
2026-08-01
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Kolbeck Roland Wilhelm
Purchase · 36.4K shares
2026-08-01
★
DIRECTOR
SCHIFF ANDREW N
Purchase · 11.6K shares
2026-06-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 1
OUTPERFORM 1
BUY 1
3 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT Wedbush OUTPERFORM HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
ALLO$2.02COMPARE
CABA$3.12COMPARE
EDIT$3.16COMPARE
NEO$18.05COMPARE
MASS$10.73COMPARE
SENS$9.33COMPARE
BIOA$9.65COMPARE
XGN$7.39COMPARE